Digital Agentic AI buoys all stakeholders in oncology, with Eron Kel... At LSX 2025, Eron Kelly, CEO of Concert AI, discussed the work his Boston-based start-up is doing in oncology.
R&D A different approach to obesity treatment, with Steffen-Seba... At LSX 2025, editor-in-chief Jonah Comstock connected with Dr Steffen Sebastian-Bolz, chief science officer at Aphaia Pharma.
R&D Why Regeneron is giving away sequencing “for free”, with Ali... Alison Fenney, executive director of strategic partnerships and business operations at Regeneron Genetics Center, discusses free genetic sequencing.
Oncology News and advice from an investor-CEO, with Milenko Cicmil pharmaphorum caught up with Milenko Cicmil to talk about Tasca Therapeutics’ news at LSX: their first patient dosed for lead asset CP-383.
R&D Driving innovation through partnership at AstraZeneca, with ... Nikhil Mutyal, head of search and evaluation for respiratory and immunology at AstraZeneca, discusses partnership and external innovation at LSX.
Digital The right AI for the right job, with Iya Khalil In a post-BIO virtual interview, Jonah Comstock speaks with Iya Khalil, VP and head of data, AI, and genome sciences at Merck & Co (MSD in Europe).
News Lilly bags FDA okay for Wegovy pill rival orforglipron Eli Lilly has claimed US approval for oral GLP-1 agonist orforglipron, setting up a market clash with Novo Nordisk's first-to-market Wegovy pill.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
